



vTv Therapeutics to Present at the International Psychogeriatric Association International Congress

09/02/16

HIGH POINT, N.C.--(BUSINESS WIRE)--Sep. 2, 2016-- vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer's disease and diabetes, today announced that company Chief Medical Officer Dr. Larry Altstiel, MD, PhD will be giving a platform presentation titled "*Clinical Support for Advancement of the RAGE Antagonist Azeliragon into Phase 3 Clinical Investigation for Mild Alzheimer's Disease*" at the International Psychogeriatric Association International Congress on Wednesday, September 7 between 10:00 and 11:30am.

The Phase 2b results of 5mg per day of azeliragon over a period of 18 months showed statistically significant benefit in mild-to-moderate Alzheimer's patients (+3.1 points on ADAS-Cog11 standard measure of cognition) and greater benefit in mild patients (+4.0 points on ADAS-Cog11), with improvements on secondary endpoints including a statistically significant reduction in psychiatric adverse events.

About vTv Therapeutics

vTv Therapeutics Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. vTv has a pipeline of clinical drug candidates led by programs for the treatment of Alzheimer's disease and Type 2 diabetes as well as treatment of inflammatory disorders and the prevention of muscle weakness.

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160902005083/en/>

Source: vTv Therapeutics Inc.

Investors

IR@vtvtherapeutics.com

or

Media

PR@vtvtherapeutics.com

or

vTv Therapeutics

Nura Strong, 336-841-0300 X164

nstrong@vTvTherapeutics.com